{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:45:07Z","timestamp":1787024707422,"version":"build-2736575974"},"reference-count":84,"publisher":"Bentham Science Publishers Ltd.","issue":"4","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2019,6,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background &amp; Introduction:<\/jats:title>\n                    <jats:p>The advent of the sodium-glucose cotransporter-2 inhibitors [SGLT-2i] provides an additional tool to combat diabetes and complications. The use of SGLT-2i leads to effective and durable glycemic control with important reductions in body weight\/fat and blood pressure. These agents may delay beta-cell deterioration and improve tissue insulin sensitivity, which might slow the progression of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods &amp; Results:<\/jats:title>\n                    <jats:p>In response to glycosuria, a compensatory rise in endogenous glucose production, sustained by a decrease in plasma insulin with an increase in glucagon has been described. Other possible mediators have been implicated and preliminary findings suggest that a sympathoadrenal discharge and\/or rapid elevation in circulating substrates (i.e., fatty acids) or some yet unidentified humoral factors may have a role in a renal-hepatic inter-organ relationship. A possible contribution of enhanced renal gluconeogenesis to glucose entry into the systemic circulation has not yet been ruled out. Additionally, tissue glucose utilization decreases, whereas adipose tissue lipolysis is stimulated and, there is a switch to lipid oxidation with the formation of ketone bodies; the risk for keto-acidosis may limit the use of SGLT-2i. These metabolic adaptations are part of a counter-regulatory response to avoid hypoglycemia and, as a result, limit the SGLT-2i therapeutic efficacy. Recent trials revealed important cardiovascular [CV] beneficial effects of SGLT-2i drugs when used in T2DM patients with CV disease. Although the underlying mechanisms are not fully understood, there appears to be \u201cclass effect\u201d. Changes in hemodynamics and electrolyte\/body fluid distribution are likely involved, but there is no evidence for anti-atherosclerotic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>It is anticipated that, by providing durable diabetes control and reducing CV morbidity and mortality, the SGLT-2i class of drugs is destined to become a priority choice in diabetes management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1573399814666180813124645","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T05:20:13Z","timestamp":1535347213000},"page":"314-327","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors"],"prefix":"10.2174","volume":"15","author":[{"given":"Eugenio","family":"Cersosimo","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Diabetes, University of Texas Health Science Center, San Antonio, TX, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Miles","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Metabolism, Endocrinology & Genetics, University of Kansas Medical Center, Kansas City, KS, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"Gerich J.E.","year":"2010","unstructured":"Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycemia of diabetes mellitus: therapeutic implications.","journal-title":"Diabet Med"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJM197003052821026","volume":"282","author":"Cahill G.F.","year":"1970","unstructured":"Cahill GF. Starvation in man.","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2174\/1573399812666160613111959","volume":"12","author":"Forst T.","year":"2016","unstructured":"Forst T, Heise T, Plum-Morschel L. Pharmacological interventions in type 2 diabetes mellitus \u2013 a pathophysiological reasoned approach.","journal-title":"Curr Diabetes Rev"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","volume":"54","author":"Rahmoune H.","year":"2005","unstructured":"Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.","journal-title":"Diabetes"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","volume":"28","author":"Morgensen C.E.","year":"1971","unstructured":"Morgensen CE. Renal tubular transport activity in type 1 diabetes.","journal-title":"Scand J Clin Lab Invest"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"Merovci A.","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.","journal-title":"J Clin Invest"},{"key":"ref=7","first-page":"81","volume":"7","author":"Cersosimo E.","year":"2014","unstructured":"Cersosimo E. Renal glucose handling and the kidney as a target for anti-diabetic medication.","journal-title":"Curr Trends Endocrinol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","volume":"67","author":"Wilding J.P.H.","year":"2013","unstructured":"Wilding JPH, Charpentier G, Hollander P. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial.","journal-title":"Int J Clin Pract"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2337\/dc15-0779","volume":"38","author":"Mathieu C.","year":"2015","unstructured":"Mathieu C, Ranetti AE, Li D. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes.","journal-title":"Diabetes Care"},{"key":"ref=10","first-page":"405","volume":"13","author":"Mathews J.C.","year":"2017","unstructured":"Mathews JC. Empagliflozin for type 2 diabetes mellitus: An overview of phase 3 clinical trials.","journal-title":"Curr Diabetes Rev"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1172\/JCI105481","volume":"45","author":"Cahill G.F.","year":"1966","unstructured":"Cahill GF, Herrera MG, Morgan AP. Hormone-fuel interrelationships during fasting.","journal-title":"J Clin Invest"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1172\/JCI106016","volume":"45","author":"Owen O.E.","year":"1969","unstructured":"Owen OE, Felig P, Morgan AP, Wahren J, Cahill GF. Liver and kidney metabolism during prolonged starvation.","journal-title":"J Clin Invest"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1172\/JCI117270","volume":"93","author":"Cersosimo E.","year":"1994","unstructured":"Cersosimo E, Judd R, Miles JM. Insulin regulation of renal glucose metabolism in conscious dogs.","journal-title":"J Clin Invest"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4158\/EP161471.RA","volume":"23","author":"Gianchandani R.Y.","year":"2017","unstructured":"Gianchandani RY, Neupane S, Iyengar JJ, Heung M. Pathophysiology and management of hypoglycemia in end stage renal disease patients: a review.","journal-title":"Endocr Pract"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2337\/diab.46.4.643","volume":"46","author":"Cersosimo E.","year":"1998","unstructured":"Cersosimo E, Molina PE, Abumrad NN. Renal lactate metabolism and gluconeogenesis during insulin-induced hypoglycemia.","journal-title":"Diabetes"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1172\/JCI118314","volume":"96","author":"Stumvoll M.","year":"1995","unstructured":"Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich JE. Uptake and release of glucose by the human kidney: post-absorptive rates and responses to epinephrine.","journal-title":"J Clin Invest"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.1152\/ajpendo.1999.276.1.E78","volume":"276","author":"Cersosimo E.","year":"1999","unstructured":"Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/diabetes.48.2.292","volume":"48","author":"Ekberg K.","year":"1999","unstructured":"Ekberg K, Landau BR, Wajngot A. Contributions by the kidney and liver to glucose production in the post-absorptive state and after 60 h of fasting.","journal-title":"Diabetes"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2337\/diabetes.50.9.2087","volume":"50","author":"Cersosimo E.","year":"2001","unstructured":"Cersosimo E, Garlick P, Ferretti J. Abnormal glucose handling by the kidney in response to hypoglycemia in type 1 diabetes.","journal-title":"Diabetes"},{"key":"ref=20","first-page":"607","volume":"11","author":"Krebs H.A.","year":"1963","unstructured":"Krebs HA, Hems RA, Gascoyne T. Renal gluconeogenesis IV: gluconeogenesis from substrate combinations.","journal-title":"Acta Biol Med Ger"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1681\/ASN.2005070742","volume":"17","author":"Eid A.","year":"2006","unstructured":"Eid A, Bodin S, Ferrier B. Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic fatty rats.","journal-title":"J Am Soc Nephrol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1152\/physrev.1986.66.2.469","volume":"66","author":"Wirthensohn G.","year":"1986","unstructured":"Wirthensohn G, Guden W. Renal substrate metabolism.","journal-title":"Physiol Rev"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/ki.2010.509","volume":"79","author":"Mather A.","year":"2011","unstructured":"Mather A, Pollock C. Glucose handling by the kidney.","journal-title":"Kidney Int Suppl"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ki.1981.100","volume":"20","author":"Klein K.L.","year":"1981","unstructured":"Klein KL, Wang MS, Torikai W, Davidson D, Kenokawa K. Substrate oxidation by isolated single nephron segments in rat.","journal-title":"Kidney Int"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ki.1984.143","volume":"26","author":"Guder W.","year":"1984","unstructured":"Guder W, Ross BD. Enzyme distribution along the nephron.","journal-title":"Kidney Int"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1042\/bj1120149","volume":"20","author":"Weiderman M.J.","year":"1969","unstructured":"Weiderman MJ, Krebs HA. The fuel of respiration of rat renal cortex.","journal-title":"Biochem J"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","volume":"280","author":"Wright E.M.","year":"2001","unstructured":"Wright EM. Renal Na(+)-glucose co-transporters.","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1016\/S0021-9258(19)41154-X","volume":"250","author":"Aronson P.S.","year":"1975","unstructured":"Aronson PS, Sacktor B. The Na+ gradient-dependent transport of D-glucose in renal brush border membranes.","journal-title":"J Biol Chem"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1152\/physrev.1994.74.4.993","volume":"74","author":"Hediger M.A.","year":"1994","unstructured":"Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose co-transporters.","journal-title":"Physiol Rev"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/ki.1989.202","volume":"36","author":"Sacktor B.","year":"1989","unstructured":"Sacktor B. Sodium-coupled hexose transport.","journal-title":"Kidney Int"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1016\/S0021-9258(17)32677-7","volume":"269","author":"Lee W.S.","year":"1994","unstructured":"Lee WS, Kanai Y, Wells RG. The high affinity Na+\/glucose co-transporter: re-evaluation of function and distribution of expression.","journal-title":"J Biol Chem"},{"key":"ref=32","unstructured":"Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low-affinity Na+-glucose co-transporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose J Clin Invest 1994; 93: 397-404."},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","volume":"61","author":"Gorboulev G.V.","year":"2012","unstructured":"Gorboulev GV, Schlormann A, Vallon V. Na+ D-glucose co-transporter SGLT-1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion.","journal-title":"Diabetes"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Al-Jobori H, Daniele G, Cersosimo E. Triplitt C, Norton L, De- Fronzo R, Abdul-Ghani M.Empagliflozin and Kinetics of Renal Glucose Transport in Healthy and Type 2 Diabetic Individuals. Diabetes 2017; 66: 1999-2006.","DOI":"10.2337\/db17-0100"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1172\/JCI102424","volume":"30","author":"Farber S.J.","year":"1951","unstructured":"Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose.","journal-title":"J Clin Invest"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","volume":"28","author":"Mogensen C.E.","year":"1971","unstructured":"Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects.","journal-title":"Scand J Clin Lab Invest"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"DeFronzo R.A.","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.","journal-title":"Nat Rev Nephrol"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","volume":"36","author":"DeFronzo R.A.","year":"2013","unstructured":"DeFronzo RA, Hompesch M, Kasichayanula S. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.","journal-title":"Diabetes Care"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"Vallon V.","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycemia: the pleiotropic effects of SGLT-2 inhibition.","journal-title":"Diabetologia"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/1573399813666170214112115","volume":"14","author":"Wang Y.","year":"2018","unstructured":"Wang Y, Wang C, Zhang X, Gu HF, Wu L. Common drugs for stabilization of renal function in the progression of diabetic nephropathy and their relations with hypertension therapy.","journal-title":"Curr Diabetes Rev"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI113157","volume":"80","author":"Rosetti L.","year":"1987","unstructured":"Rosetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.","journal-title":"J Clin Invest"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"Ehrenkranz J.R.L.","year":"2005","unstructured":"Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: A review.","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","volume":"48","author":"Oku A.","year":"1999","unstructured":"Oku A, Ueta K, Arakawa K. T-1095, an inhibitor of renal Na+-glucose co-transporters may provide a novel approach to treating diabetes.","journal-title":"Diabetes"},{"key":"ref=44","first-page":"285","volume":"8","author":"Isaji M.","year":"2007","unstructured":"Isaji M. Sodium-glucose co-transporter inhibitors for diabetes.","journal-title":"Curr Opin Investig Drugs"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1021\/jm990175n","volume":"42","author":"Tsujhara K.","year":"1999","unstructured":"Tsujhara K. Na-glucose co-transporter (SGLT) inhibitors as anti-diabetic agents. Synthesis and pharmacological properties of 4\u2032-dihydroxyphlorizin derivatives substituted on the B ring.","journal-title":"J Med Chem"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.109.029165","volume":"38","author":"Obermeier M.T.","year":"2010","unstructured":"Obermeier MT, Yao M, Khanna A. characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II (SGLT2) inhibitor, in animals and humans.","journal-title":"Drug Metab Dispos"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0091270011400604","volume":"52","author":"Ghosh R.K.","year":"2012","unstructured":"Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. New drug\u2013drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.","journal-title":"Clin Pharmacokinet"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","volume":"53","author":"Devineni D.","year":"2013","unstructured":"Devineni D, Curtin CR, Polidori D. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co\u2010transporter-2 inhibitor, in subjects with type 2 diabetes mellitus.","journal-title":"J Clin Pharmacol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"Scheen A.J.","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of Sodium\u2013Glucose Co-Transporter Type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.","journal-title":"Drugs"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","volume":"54","author":"Scheen A.J.","year":"2015","unstructured":"Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of sglt2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.","journal-title":"Clin Pharmacokinet"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","volume":"36","author":"Polidori D.","year":"2013","unstructured":"Polidori D, Sha S, Mudaliar S. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion.","journal-title":"Diabetes Care"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","volume":"61","author":"Liu J.J.","year":"2012","unstructured":"Liu JJ, Lee TW, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?","journal-title":"Diabetes"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"Komoroski B.","year":"2009","unstructured":"Komoroski B, Vachharanji N, Boulton D. Dapagliflozin, a novel SGLT2 inhibitor induces dose-dependent glycosuria in healthy subjects.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4155\/cli.10.12","volume":"1","author":"Kipnes M.S.","year":"2011","unstructured":"Kipnes MS. Sodium-glucose co-transporter 2 inhibitor in the treatment of type 2 diabetes: a review of Phase II and III trials.","journal-title":"Clin Invest"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"Bailey C.J.","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, double-blind, placebo-controlled trial.","journal-title":"Lancet"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","volume":"34","author":"Nauck M.","year":"2011","unstructured":"Nauck M, Del PS, Meier JJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin.","journal-title":"Diabetes Care"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","volume":"35","author":"Rosenstock J.","year":"2012","unstructured":"Rosenstock J, Aggarwal N, Polidori D. Dose-ranging effects of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.","journal-title":"Diabetes Care"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","volume":"38","author":"Ferrannini G.","year":"2015","unstructured":"Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium\u2013glucose co-transporter 2 inhibition.","journal-title":"Diabetes Care"},{"key":"ref=59","unstructured":"Del Prato S. SGLT-2 Inhibitors Show Durability in Glycemic Control, Weight-Loss Maintenance After 4 Years. American Diabetes Association Annual Meeting. Chicago. 2016."},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"Bolinder J.","year":"2012","unstructured":"Bolinder J, Ljunggren O, Kullberg J. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes with inadequate glycemic control on metformin.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"Vallon V.","year":"2015","unstructured":"Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.","journal-title":"Annu Rev Med"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"Vallon V.","year":"2014","unstructured":"Vallon V, Gerasimova M, Rose MA. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","volume":"9","author":"Terami N.","year":"2014","unstructured":"Terami N, Ogawa D, Tachibana H. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice.","journal-title":"PLoS One"},{"key":"ref=64","doi-asserted-by":"crossref","unstructured":"Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2016; [http:\/\/dx.doi.org\/doi:10.1681 \/ASN.2016030278]","DOI":"10.1681\/ASN.2016030278"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"Cherney D.Z.I.","year":"2014","unstructured":"Cherney DZI, Perkins BA, Soleymanlou N. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.","journal-title":"Circulation"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","journal-title":"N Engl J Med"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"Mahaffey K.W.","year":"2018","unstructured":"Mahaffey KW, Neal B, Perkovic V. Canagliflozin for primary and secondary prevention of cardiovascular events.","journal-title":"Circulation"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"Ferrannini E.","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S. Metabolic response to sodium-glucose co-transporter 2 inhibition in type 2 diabetic patients.","journal-title":"J Clin Invest"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2337\/dc07-1683","volume":"31","author":"Sheikh-Ali M.","year":"2008","unstructured":"Sheikh-Ali M, Karon BS, Basu A. Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?","journal-title":"Diabetes Care"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"Peters A.L.","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose co-transporter 2 inhibition.","journal-title":"Diabetes Care"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","volume":"22","author":"Handelsman Y.","year":"2016","unstructured":"Handelsman Y. The american association of clinical endocrinologists and american college of endocrinology position statement on the association of sglt-2 inhibitors and diabetic ketoacidosis.","journal-title":"Endocr Pract"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"Neal B.","year":"2018","unstructured":"Neal B, Perkovic V. Mahaffey KW on behalf of the CANVAS Program Collaborative Group. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).","journal-title":"Circulation"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dc16-0041","volume":"39","author":"Abdul-Ghani M.","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-Reg outcome study.","journal-title":"Diabetes Care"},{"key":"ref=74","author":"Kosiborod M.","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ. Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study.","journal-title":"Circulation"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/cvr\/cvx149","volume":"114","author":"Bertero E.P.","year":"2018","unstructured":"Bertero EP, Roma L, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.","journal-title":"Cardiovasc Res"},{"key":"ref=76","first-page":"130","volume":"21","author":"Aloia J.F.","year":"1980","unstructured":"Aloia JF, Cohn SH, Abesamis C, Babu J, Zanzi I, Elllis K. Total body sodium and sodium excess.","journal-title":"J Nucl Med"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"Ferrannini E.","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG outcome trial: A \u201cThrifty substrate\u201d hypothesis.","journal-title":"Diabetes Care"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","volume":"85","author":"Stanley W.C.","year":"2005","unstructured":"Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart.","journal-title":"Physiol Rev"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3945\/ajcn.116.133561","volume":"104","author":"Kevin D.","year":"2016","unstructured":"Kevin D, Hall KD, Chen KY. Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men.","journal-title":"Am J Clin Nutr"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Frias J.P.","year":"2016","unstructured":"Frias JP, Guja C, Hardy E. Exenatide once weekly plus dapagliflozin once daily exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised controlled trial.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/dom.13294","volume":"20","author":"Li D.","year":"2018","unstructured":"Li D, Shi W, Wang T, Tang H. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.","journal-title":"Diabetes Obes Metab"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/2230-8210.172268","volume":"20","author":"John M.","year":"2016","unstructured":"John M, Gopinath D, Jagesh R. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","volume":"377","author":"Garg S.K.","year":"2017","unstructured":"Garg SK, Henry RR, Banks P. Effects of sotagliflozin added to insulin in patients with type 1 diabetes.","journal-title":"N Engl J Med"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"Marso S.P.","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K. Liraglutide and cardiovascular outcomes in type 2 diabetes.","journal-title":"N Engl J Med"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/164636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T06:37:55Z","timestamp":1661841475000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/164636\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,6,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399814666180813124645","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}